A 38-year-old woman with hypertension is started on a beta-blocker. After 2 weeks, she reports persistent fatigue and bradycardia (HR 48/min). The physician suspects altered receptor sensitivity due to chronic beta-blocker exposure. Which investigation is most appropriate to confirm the presence of receptor upregulation and assess the pharmacodynamic response?

Explanation

## Investigation of Choice: Radioligand Binding Assay ### Why This Is Correct **Key Point:** Radioligand binding assays directly measure receptor density and affinity on cell membranes, providing quantitative evidence of receptor upregulation (increased Bmax) or downregulation (decreased Bmax) in response to chronic drug exposure. In chronic beta-blocker use, sustained antagonism of β-adrenergic receptors triggers compensatory upregulation—an increase in the total number of receptors (Bmax increases while Kd remains unchanged). Radioligand binding assays using radiolabeled ligands (e.g., ³H-dihydroalprenolol) can measure this change directly on lymphocyte membranes, which express β₂-adrenergic receptors and serve as a surrogate tissue. **High-Yield:** Radioligand binding is the gold-standard in vitro method for quantifying receptor density and kinetics. It yields two critical parameters: - **Bmax** (maximum binding capacity) — reflects total receptor number - **Kd** (dissociation constant) — reflects affinity; unchanged in upregulation ### Mechanism of Receptor Upregulation ```mermaid flowchart TD A[Chronic Beta-Blocker Exposure]:::action --> B[Sustained β-Adrenergic Receptor Blockade]:::outcome B --> C[Reduced Intracellular cAMP]:::outcome C --> D[Loss of Negative Feedback on Gene Transcription]:::outcome D --> E[Increased Receptor Synthesis]:::action E --> F[Receptor Upregulation<br/>Bmax ↑, Kd unchanged]:::outcome F --> G[Radioligand Binding Assay<br/>Detects ↑ Bmax]:::action ``` ### Clinical Pearl Receptor upregulation explains **rebound hypertension** and **tachycardia** upon abrupt beta-blocker withdrawal—the excess receptors suddenly become unblocked, causing a surge in sympathetic responsiveness. Gradual tapering allows downregulation to occur. ### Why Lymphocytes? Lymphocytes are easily accessible (blood draw) and express β₂-adrenergic receptors; they serve as a surrogate tissue for assessing systemic receptor changes without invasive cardiac biopsy. --- ## Comparison of Investigation Options | Investigation | What It Measures | Relevance to Receptor Upregulation | |---|---|---| | **Radioligand binding assay** | Receptor density (Bmax) and affinity (Kd) on cell membranes | **Direct, quantitative evidence of upregulation** | | Plasma catecholamine levels | Circulating epinephrine and norepinephrine concentration | Indirect; may be elevated due to upregulation, but does not prove receptor changes | | Serum beta-blocker concentration | Drug level in blood | Confirms drug exposure, not receptor response | | Cardiac stress test | Cardiac contractility and HR response to sympathomimetic stimulus | Functional assessment; does not quantify receptor density | --- **Citation:** KD Tripathi 8e Ch 2 (Pharmacodynamics and Receptor Theory)